HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis
Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes. Objectives: This study aimed to evaluate the cost-effectiveness o...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Acceso en liña: | https://doi.org/10.1177/17588359251356109 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|